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Adenomatous polyposis coli (APC) gene mutations have
been implicated in familial and sporadic gastrointestinal
(GI) cancers. APC mutations are associated with auto-
somal dominant inheritance of disease in humans.
Similarly, mice that contain a single mutant APC gene
encoding a protein truncated at residue 716 (Apc
D716)
develop multiple polyps throughout the GI tract as early
as 4 weeks after birth. Inactivation of another tumor
suppressor gene, Hypermethylated in Cancer 1 (HIC1),
often occurs in human colon cancers, among others, via
CpG island hypermethylation. Homozygous deletion of
Hic1 in mice results in major developmental defects and
embryonic lethality. Hic1 heterozygotes have previously
been shown to develop tumors of a variety of tissue types.
We now report that loss of a single Hic1 allele can
promote crypt hyperplasia and neoplasia of the GI tract,
and Hic1
þ/ , Apc
þ/D716 double heterozygotes (DH)
develop increased numbers of polyps throughout the GI
tract at 60 days. Hic1 expression is absent in polyps from
DH mice, with concomitant increased expression of two
transcriptional repression targets of Hic1, Sirt1 and Sox9.
Together, our data suggest that loss of a gene frequently
silenced via epigenetic mechanisms, Hic1, can cooperate
with loss of a gene mutated in GI cancer, Apc, to promote
tumorigenesis in an in vivo model of multiple intestinal
neoplasia.
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Introduction
The tumor suppressor gene Hypermethylated in Cancer 1
(HIC1) is inactivated by CpG island hypermethylation
in a variety of human cancers (Wales et al., 1995). HIC1
resides in a region of chromosome 17p13 frequently
targeted for allelic loss in human cancer (Wales et al.,
1995). This region is also associated with the Miller–
Dieker Syndrome, a congenital disorder characterized
by severe facial and neurologic deﬁcits (Carter et al.,
2000; Chen et al., 2003). Homozygous deletion of Hic1
in mice results in major developmental defects and
embryonic lethality (Carter et al., 2000). HIC1 hetero-
zygous mice retaining one allele of Hic1, develop age-
and gender-dependent tumors associated with promoter
hypermethylation and gene silencing of the remaining
wild type (WT) HIC1 allele (Chen et al., 2003, 2004;
Briggs et al., 2008). These studies suggest that Hic1
has important roles both in development and tumor
suppression.
Mutations in the adenomatous polyposis coli (APC)
gene have been implicated both in familial as well as
sporadic gastrointestinal (GI) cancers. APC mutations
are associated with autosomal dominant inheritance of
disease in humans. Similarly, mice that contain a single
mutant Apc gene encoding a protein truncated at amino
acid residue 716 (Apc
D716) develop multiple polyps
throughout the GI tract as early as 4 weeks after birth
(Oshima et al., 1995; Wu et al., 2009). A major function
of APC in human cells is to regulate Wnt signaling in
stem cells and cancer by preventing the nuclear
translocation of b-catenin (reviewed in (Gregorieff and
Clevers, 2005; Reya and Clevers, 2005)). As expected,
polyps derived from mice with a disruption in Apc
function (Apc
min and Apc
D716 ), display nuclear b-catenin,
typically associated with dysregulated Wnt signaling
(Su et al., 1992; Oshima et al., 1995).
Hic1 is a sequence-speciﬁc transcriptional repressor
with an N-terminal POZ domain, and ﬁve C2H2 zinc-
ﬁngers at the C-terminus (Deltour et al., 1998, 1999,
2002). A growing body of evidence suggests that one
important function of HIC1 is to inhibit the canonical
Wnt signaling pathway. Recent studies in mammalian
cell lines suggest that HIC1 antagonizes Wnt signaling
through association with TCF4 and b-catenin in a
transcriptionally inactive complex retained in the
nucleus (Valenta et al., 2006). Moreover, our previous
studies have shown that knockdown of SIRT1, an
important repressive target of HIC1 (Chen et al.,
2005), in breast and colon cancer cells leads to the
reactivation of the epigenetically silenced Wnt antago-
nists, sFRPs (Pruitt et al., 2006). Together, these data
suggest that Hic1 can also ﬁne-tune the Wnt pathway in
cancer cells.
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www.nature.com/oncWe now report that loss of a single Hic1 allele can
promote crypt hyperplasia of the small intestine and
further potentiate polyp formation in Apc
þ/D716 mice.
Hic1
þ/ , Apc
þ/D716 double heterozygous (DH) mice
develop increased numbers of polyps throughout the
GI tract by 60 days. Hic1 is not expressed in polyps with
an increase in DNA, and immunohistochemical analyses
of polyps show increases in markers such as b-catenin,
Sirt1 and Sox9, indicating aberrant Wnt and Hic1
signaling. Together, our data suggest that loss of a gene
frequently silenced via epigenetic mechanisms, Hic1,
can cooperate with loss of a gene often mutated in GI
cancer, Apc, to promote tumorigenesis in an in vivo
model of multiple intestinal neoplasia.
Results
DH mice develop increased numbers of polyps throughout
the GI tract
Loss of a single Hic1 allele complements loss of Apc
function to promote acceleration of polyp formation in
60-day-old Hic1
þ/ , Apc
þ/  mice. In all four genotypes
generated from the cross between Hic1
þ/  females and
Apc
þ/D716 male mice, the greatest numbers of polyps in
both the small (Figures 1a and d) and large (Figures 1b
and d) intestines were present in the GI tracts of DH
mice. At this age, no polyps were detected in Hic1
þ/ 
mice, and WT controls do not develop polyps at any age
studied. Hic1
þ/  mice do, however, develop a few polyps
by 90 days of age, but the number of tumors is greater in
Apc
þ/D716 and DH mice (Supplementary Figure S1). At
60 days, the majority of polyps in Apc
þ/D716 mice were
found in the small intestine, as reported previously
(Oshima et al., 1995), and the size is predominantly
small (o2mm) (Figures 2a–d). DH mice, however,
develop increased numbers of polyps throughout all
regions of the small and large intestine (Figures 2a–d).
Notably, in the large intestine, there were several large
polyps over 2 and 3mm in DH, with none greater than
3mm in the single Apc
þ/D716 (Figure 2d). This involve-
ment of the colon is more reminiscent of the spectrum of
human GI cancers.
Sirt1 and Hic1 expression are inverse to one another in
normal GI tissue
Immunohistochemical analyses reveal that in WT mice
Hic1 expression is largely restricted to the stromal and
inﬂammatory cells in lamina propria in the small
intestine, with only occasional nuclear staining in
epithelial cells (Figure 3a). By real-time PCR analysis
of Hic1 expression within the small intestine, within
some variability in levels, values were not statistically
different for WT and Hic1
þ/  mice (Figure 3e). How-
ever, there is a statistically signiﬁcant change in terms
of decreased Hic1 expression in DH mice (Figure 3e).
In the colon, by immunohistochemistry, Hic1 is highly
visible in cells in the upper crypt and intercrypt table
containing more mature epithelial cells (Figure 3b),
whereas it is low to undetectable near the base of the
colonic crypts, where progenitor cells reside (Ponder
et al., 1985; Barker et al., 2008, 2009).
In this above setting, we examined the distribution of
nuclear Sirt1, a transcription repression target of Hic1
(Chen et al., 2005). In the small intestine, the protein is
expressed throughout the progenitor crypt regions and
mature villus epithelial cells (Figure 3c). In Hic1
þ/  mice
and DH mice, which have only one functional copy
of Hic1, the distribution of Sirt1 remains unchanged,
but there is a distinct increase in the intensity of Sirt1
staining throughout the crypt and mature villus
epithelial region. A much more striking inverse pattern
for Hic1 and Sirt1 is observed in normal mouse colon
mucosa. Hic1 expression in the large intestine is highest
in WT animals, whereas the lowest expression appears
to be restricted to mice that have only one functional
allele of Hic1 (Hic1
þ/  and DH) (Figure 3b). Further-
more, in the WT mice, Hic1 expression is inverse to that
of Sirt1, which is more restricted to colonic basal crypt
regions, and its expression gradually decreases as cells
migrate toward the upper crypt, where the cells express
Hic1 (Figure 3d). Inverse to the decreased Hic1
expression in mice with one functional Hic1 allele, Sirt1
expression throughout the large intestine appears to
have regionally expanded to the more mature cells
above the upper crypt in Hic1
þ/  and DH mice (Figures
3b and d). Together, these data suggest that Hic1 and
Sirt1 maintain an inverse relationship in the GI tract
and, notably, that the reduction in Hic1 expression in
the GI tract of Hic1
þ/  and DH mice conveys a
functional consequence for Sirt1 distribution in this
tissue.
Hic1 methylation in normal and neoplastic tissue
In previous settings, loss of Hic1 expression in tumors in
Hic1
þ/  mice, and in many human tumors (Fujii et al.,
1998; Dong et al., 2001), has been associated with DNA
hypermethylation of either an upstream (Hic1a) or
downstream (Hic1b) promoter region (Chen et al.,
2003). Both regions are associated with exons, which
are transcribed (Guerardel et al., 2001), and hyper-
methylation of either can correlate with complete loss of
transcripts for the gene (Chen et al., 2003; Briggs et al.,
2008). As detailed in the earlier studies, bisulﬁte
sequence analysis can distinguish the WT Hic1b region
from the targeted allele, but cannot separate WT Hic1a
from the disrupted allele (Chen et al., 2003; Briggs et al.,
2008). To elucidate whether methylation may have a
role in the reduced Hic1 expression in the small and
large intestine, as described, or in the increased polyps
observed in DH animals, we assessed the methylation
status of Hic1 in the current study using bisulﬁte
sequence analysis, as described previously (Chen et al.,
2003; Briggs et al., 2008). Although the overall density
of methylation is not dramatic, we do observe the
greatest increase in methylation for Hic1a, both in
polyps from the small and large intestine of DH mice
relative to WT animals as well as Apc
þ/D716 (Figures 4a
and b). Interestingly, normal small intestine from
Hic1
þ/  as well as from DH animals also displays
greater methylation relative to WT animals (Figure 4b),
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Oncogenecorresponding to the decreased expression observed by
real-time PCR (Figure 3e). The WT Hic1b region,
however, is variably more methylated than Hic1a in
both the normal small and large intestines in mice of all
genotypes (Figures 4c and d). As noted above, there is
minimal detectable expression of Hic1 (Figure 3a) in
normal small intestine, but this low level appears to be
further reduced in the DH animals (Figure 3e).
Hic1 heterozygotes develop crypt hyperplasia
Despite the lack of signiﬁcant Hic1 expression in the
small intestine, it remains clear that the genetic loss of a
single Hic1 allele potentiates polyp development. A key
ﬁnding that may provide some additional insight into
the acceleration of polyps in DH mice within the small
intestine emerged when we analyzed the proliferation
status of the GI tract. Ki67, a hallmark of proliferation,
(Barnard et al., 1987), was positive in all polyps
examined (data not shown) and, as expected, restricted
to the more proliferative cells in the normal intestinal
crypts (Figure 5a). Interestingly, the loss of a single Hic1
allele leads to crypt hyperplasia. This hyperplasia
manifests, in Hic1
þ/  and DH mice, as increased
numbers of crypts per villi (Figures 5a and b). No
obvious changes in the total number of villi were
observed. These hyperplastic crypts have little or no
Hic1, whereas Sirt1 expression is abundant (Figure 3).
We examined crypts from all genotypes for potential
alterations in the progenitor cell marker, Lgr5 (Barker
et al., 2007), and found similar numbers of Lgr5 positive
cells, suggesting no direct effect of Hic1 allelic loss on
this sub-population within each crypt unit (data not
shown). However, we did ﬁnd features associated with
crypt dysplasia (Hao et al., 2005) in Hic1
þ/  small
intestines (Supplementary Figure S2), as well as a small
number of polyps (Supplementary Figure S1). This
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Figure 1 DH mice develop more polyps than Apc mice. (a) Methylene blue staining of intestinal sprays collected from small intestines
of WT, Apc
þ/D716(Apc), Hic1
þ/  (Hic1), and DH Apc
þ/D716, Hic1
þ/  (DH) mice at 60 days. Sample sizes were as follows: WT, n¼12;
Hic1, n¼13; Apc, n¼7; DH, n¼8. Arrows indicate polyps. (b) Methylene blue staining of intestinal sprays collected from large
intestines of WT, Apc, Hic1 and DH mice at 60 days. Arrows indicate polyps. (c) Values represent the mean number of polyps±s.e.m.
throughout the entire GI tract as counted under a dissection microscope. (d) Values represent the mean number of polyps±s.e.m. in
the small or large intestine as indicated. Statistics were carried out as detailed in materials and methods. Comparisons were considered
statistically signiﬁcant at a *P-value o0.05.
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Oncogenesuggests that the loss of Hic1 alone may be signiﬁcant in
the development of GI tumors at this early age and,
as previously observed, in much older animals as well
(Chen et al., 2003).
Polyps do not express Hic1 and display hallmarks of
aberrant Hic1 and Wnt signaling
As expected, based on the increase in methylation
observed for Hic1a in both the large and small intestine
(Figure 4) and the absence of Hic1 expression in normal
small intestine, polyps from Hic1
þ/  and DH mice did
not express detectable Hic1 (Figure 6a). Small intestine
polyps from Apc
þ/D716 also did not express Hic1 (Figure 6a).
In the normal and neoplastic tissue from Apc
þ/D716 mice,
however, this may be due to a chromatin-based
repressive mechanism surrounding the Hic1a region,
as there was no increase in DNA methylation for
this genotype (Figure 4). Apc
þ/D716 polyps and tumors
from DH mice showed nuclear b-catenin, a hallmark of
increased Wnt signaling (Polakis, 2000) (Figure 6a).
Interestingly, polyps from Hic1
þ/  mice also contained
nuclear b-catenin, suggesting that Wnt signaling is also
hyperactive in the neoplasms from this genotype
(Figure 6a).
As polyps derived from Hic1
þ/ , Apc
þ/D716 and DH
mice had no detectable Hic1 expression, we next
examined polyps expression of known transcriptional
repression targets of Hic1. As described previously
(Chen et al., 2005) and above, Sirt1 expression is
inversely related to the presence of Hic1 in normal GI.
We ﬁnd that, concordant with the absence of Hic1, Sirt1
expression is retained in polyps across all genotypes
(Figure 6a).
We further extended our analysis to Sox9, reported as
having reduced gene expression in a microarray screen
following Hic1 overexpression in U2OS osteosarcoma
cells (Van Rechem et al., 2009). Sox9 is a transcription
factor found in Paneth cells as well as progenitor cells in
intestinal crypts (Bastide et al., 2007). As the above
array data was not veriﬁed or characterized, we ﬁrst
validated that Sox9 is truly a Hic1 target gene and that
this relationship exists in the GI. As analyzed by
immunohistochemistry, Sox9 expression, similar to Sirt1
in normal large intestine, is inverse to the distribution of
Hic1 (Supplementary Figure S3). This protein is also
restricted to the nuclei of crypt cells and decreases in
more mature cells that express Hic1. Also, like Sirt1,
Sox9 was highly expressed in all polyps from Hic1
þ/ ,
Apc
þ/D716 and DH mice coupled with the absence of Hic1
expression (Figure 6d). Analysis of the sequence
provided by the UCSC genome browser revealed the
presence of several potential Hic1-binding sites (Pinte
et al., 2004; Chen et al., 2005) upstream of the SOX9
transcriptional start site. Sox9 expression was increased
by greater than twofold in knockout Hic1
 /  MEFs
(Figure 6b). Additionally, SOX9 was repressed upon
ectopic overexpression of Hic1 in HCT116 human colon
cancer cells that do not express endogenous Hic1
(Figure 6c). Chromatin immunoprecipitation (ChIP)of
the ectopically expressed protein to several of the
sequence-binding regions for HiC1 upstream of the
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Figure 2 DH mice have more polyps of all sizes in all regions of
the GI tract. (a) Values represent the mean number of polyps±
s.e.m. throughout the proximal small intestine or duodenum
counted at 60 days. Polyp size ranges are as indicated. White and
black columns indicate Apc
þ/D716 and DH (respectively). (b) Values
represent the mean number of polyps±s.e.m. throughout the
medial small intestine or jejunem. Polyp size ranges are as
indicated. White and black columns indicate Apc and DH
(respectively). (c) Values represent the mean number of polyps±
s.e.m. throughout the distal small intestine or ileum. Polyp size
ranges are as indicated. White and black columns indicate Apc and
DH (respectively). (d) Values represent the mean number of
polyps±s.e.m. throughout the large intestine or colon. Polyp size
ranges are as indicated. White and black columns indicate Apc and
DH (respectively). Statistics were carried out as detailed in
materials and methods. Comparisons were considered statistically
signiﬁcant at a *P-value o0.05 or **P-value o0.1.
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Figure 3 Hic1 and Sirt1 expression throughout the GI tract. (a) Hic1 immunohistochemistry of parafﬁn-embedded small intestine
sections from mice as indicated. (b) Hic1 immunohistochemistry of parafﬁn-embedded large intestine sections. (c) Sirt1
immunohistochemistry of parafﬁn-embedded small intestine. (d) Sirt1 immunohistochemistry of parafﬁn-embedded large intestine.
Genotypes of mice are as indicated for all panels. Scale bar¼50mm for all panels. (e) Realtime PCR expression of Hic1 in small
intestine. Values represent the mean fold change±s.e.m. for triplicates relative to actin. Genotypes of animals are as indicated. Tissue
was analyzed from two WT animals, three Hic1, three Min and three DH (*Po0.05).
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OncogeneSOX9 gene correlated with this ﬁnding (Supplementary
Figure S4).
Discussion
In the current study, we have established a mouse model
in which loss of function for Hic1 augments the role of
Apc loss for development of GI tumors. Importantly,
this effect of Hic1 loss of function accentuates not only
the tumorigenesis in the small intestine, which dominates
in Apc
þ/D716 mice, but also increases both the number
and size of polyps in the large intestine. These results are
consistent with our previous work, indicating that Hic1
can serve a tumor-suppressive function through a
variety of important mechanisms involving its role for
transcriptional repression of multiple downstream tar-
gets (Carter et al., 2000; Chen et al., 2003, 2004; Briggs
et al., 2008).
The role of Hic1 in the above model may be to
provide a cellular setting that provides Apc loss an
optimal opportunity for exerting an oncogenic stimulus.
Recently, Clevers et al. have shown that loss of Apc in
mouse intestine is most tumorigenic when engineered to
target intestinal stem cells (Barker et al., 2009). The loss
of one Hic1 allele appears to increase the number of
stem cell-containing crypt cell compartments and lead to
some dyplastic features in these regions. This scenario
may thus increase the target cell population susceptible
to the oncogenic effects of Apc disruption. Presumably,
this setting may favor the addiction of intestinal stem
cells to increased Wnt pathway activity driven by loss of
Apc function. Interestingly, Hic1
þ/  mice also develop
polyps (Supplementary Figure S1), and spontaneous GI
cancers appear in older Hic1
þ/  animals (Chen et al.,
2003), suggesting that the crypt hyperplasia and
dysplasia are signiﬁcant even without the additional
genetic contribution from Apc
þ/D716.
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Figure 4 Hic1 methylation analysis by bisulﬁte sequencing. (a) Left panel: representative alleles for Hic1a for bisulﬁte sequencing of
DNA from normal small intestine and small intestine polyps. Each square along a horizontal row¼a CpG site in a TA cloned allele
with white¼unmethylated and black¼methylated. Alleles are from non-polyp DNA from WT (W), Hic1
þ/  (H), Apc
þ/D716 (A), polyps
from Apc
þ/D716 (AP), non-polyp DH mice (D) and DH polyps (DP), respectively. Right panel: shown are representative alleles for
Hic1a in normal large intestine and large intestine polyp DNA (right) with alleles listed as for left panel. (b) Percent methylation
(Y-axis),with bars¼±s.e.m., per alleles shown in A and, on the X axis, 1¼W, 2¼H, 3¼A, 4¼AP, 5¼D and 6¼DP. An average of
68 alleles was sequenced for each genotype. (c) Representative alleles for Hic1b bisulﬁte sequencing in the small intestine (left), and
large intestine (right), respectively, with allele symbols as in A. (d) Percent methylation per allele for Hic1b with axes and symbols
exactly as in B. For all graphs: *Po0.05 relative to WT. An average of 20 alleles was sequenced for each genotype.
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OncogeneHic1 is not only a critical developmental protein, but
is emblematic, for human cancers, of a tumor suppressor
gene for which loss of function arises through epigenetic
rather than genetic alterations (Wales et al., 1995). Loss
of Hic1 expression in colon cancer, speciﬁcally, has also
been associated with silencing associated with DNA
hypermethylation (Nosho et al., 2009) (Maekawa et al.,
2001). In the particular mouse model described here, the
mechanism for the silencing of the remaining WT allele
of Hic1 in tumors is not yet as clear as in previous
studies of our Hic1 heterozygous mice (Chen et al.,
2003; Briggs et al., 2008). In our earlier work,
dense methylation of the proximal promoter of the
WT allele of the gene has almost always been present
in the different tumor types that arise in these mice
alone, or when they are crossed with other tumor-prone
mice (Chen et al., 2004; Briggs et al., 2008). In the
present case, the increases we ﬁnd in tumors for Hic1
promoter DNA methylation are quite small in both
promoter regions studied. Although these changes may
still be signiﬁcant for loss of gene transcription, they
accompany other chromatin changes that aid in gene
silencing.
Another puzzling feature for expression of Hic1 in
our model is the difference between normal small
and large intestine. In the latter, a clear pattern is
present, wherein Hic1 is expressed in the more
differentiated cells of the more luminal region, whereas,
interestingly, the transcriptional repression targets we
studied, Sirt1 and Sox 9, are expressed in the stem cell-
containing crypt regions. These latter proteins seem to
lose this regional distribution in the Hic1 heterozygous
mice, consistent with a modulatory role for Hic1 in their
expression patterns. However, despite the clear crypt
region changes we observe in the small intestine of the
Hic1
þ/  mice, Hic1 protein expression is below detec-
tion by immunohistochemistry in the epithelial cells.
However, there is a reduction in Hic1 mRNA expression
in DH animals by real-time PCR. Thus, we suspect
that a small amount of protein may be functional in
this region, because loss of a single WT Hic1 allele
affects the number of small intestine crypts, causing
some changes in Sirt1 and Sox9 expression patterns, and
clearly complements tumorigenicity in the DH animals.
Previous studies from others, as well as our work,
have identiﬁed a number of relevant targets of Hic1 in a
variety of biological contexts. In the cerebellum of mice,
loss of this protein leads to increased levels of the
downstream repression target gene, Atonal Homolog 1.
These changes complement loss of the Sonic Hedgehog
receptor, PATCHED, to increase the numbers of
progenitor cells and augment cerebellar tumorigenesis
(Briggs et al., 2008). Hic1 loss also associates with
spatial disruption of the downstream repression target,
ephrin A1 (Zhang et al., 2010), which is a key patterning
morphogen in development. However, in our present
model, the molecular mechanisms by which Hic 1 loss
exerts changes in the intestine are not yet clear. As we
show, two known repression target genes of Hic1, Sirt1
(Chen et al., 2005) and Sox9 (Van Rechem et al., 2009)
are both highly expressed in nuclei of tumor cells in the
Hic1
þ/ , Apc
þ/  mice. Sirt1, a mammalian ortholog of
the yeast Sir2 protein, is a direct transcriptional target
of Hic1 (Chen et al., 2005). The role for Sirt1 in
tumorigenesis has proven substantially complex to
understand as both Sirt1 knockout and overexpression
systems have yielded discordant results. A study in
which Sirt1 knockout animals were crossed to Apc
min/þ
mice showed that loss of Sirt1 had no effect on polyp
number in Apc
min/þ animals, but that polyp size was
decreased (Boily et al., 2009). These data suggest a pro-
tumorigenic role for Sirt1 in this system. Additional
work has recently linked Sirt1 to repression of the Wnt
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Figure 5 Hic1 heterozygous mice develop crypt hyperplasia of the
small intestine. (a) Shown are sections from small intestine stained
with an antibody against Ki67 for mice as indicated. Scale
bar¼50mm. (b) The number of crypts and villi per ﬁeld were
counted by two independent observers. Nine ﬁelds from three
animals within each genotype were used in counting. Values
represent the mean number of crypts per villi þ/ s.e.m. in the
small intestine. Asterisks indicate Po0.05 by Student’s t-test.
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Oncogeneinhibitors, disheveled, providing an additional Wnt-
related mechanism by which Sirt1 may promote
tumorigenesis (Holloway et al., 2010). However, another
study showed the opposite effect, in that polyps were
decreased in Apc
min/þ animals upon overexpression of
Sirt1 in the intestine (Firestein et al., 2008). Although
the role for Sirt1 in GI tumor initiation and progression
may remain controversial, in our current study, sig-
niﬁcant Sirt1 expression is present in all polyps and
inversely correlates with Hic1 expression. Thus, either
the protein has an oncogenic role in this setting or, if it is
a tumor suppressor, it is ineffectual because of lack of
signaling to downstream targets.
Sox9 has been shown to be repressed by greater than
threefold in U2OS osteosarcoma cells infected with
Ad-HIC1 (Van Rechem et al., 2009). In this regard, we
now conﬁrm Sox9 as a direct Hic1 target gene for
transcriptional repression in human colon cancer cells
and mouse MEFs by both expression analysis and ChIP.
This high-mobility group box transcription factor has
been described in the GI tract as a Wnt pathway target
(Blache et al., 2004) and, thus, this gene may be co-
regulated by both Hic1 and Wnt signaling. Sox9
expression appears to positively correlate with b-catenin
expression in human colorectal cancer (Lu et al., 2008).
A recent study also showed that SOX9 represses
expression of protein kinase C alpha in proliferating
intestinal epithelial cells (Dupasquier et al., 2009), a gene
that, in Apc
min/þ mice, may provide a protective role
against intestinal tumorigenesis (Oster and Leitges,
2006). Sox9 serves as an important crypt-related
transcription factor through its ability to repress genes
associated with differentiation (Blache et al., 2004), and
an imbalance in Sox9 expression gives rise to crypt
dysplasia (Bastide et al., 2007). This may be tightly tied
to our current ﬁnding that crypt hyperplasia is coupled
with crypt dysplasia in our Hic1
þ/  mice.
In summary, we describe, in a mouse model, an
oncogenic interaction between loss of function for the
Hic1 and Apc genes. This complementation appears
fueled by increases in crypt cell regions due to the Hic1
disruption. We associate increases in two Hic1 tran-
scriptional repression targets, Sirt1 and Sox9,w i t h
changes in the above model, but their direct roles remain
to be deﬁned for the tumorigenic events studied. Our
mouse model will prove extremely valuable for explor-
ing this and other questions linking Hic1 and the Wnt
pathway to intestinal tumorigenesis.
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Figure 6 Polyps display hallmarks of aberrant hic and wnt signaling. (a) Immunohistochemistry of parafﬁn-embedded polyps from
small intestine (SI) and large intestine (LI) for antibodies as indicated. Genotypes of mice are as indicated. Scale bar¼50mm. (b) Real-
time PCR expression for Sox9 in MEFs. Values represent the mean fold change±s.e.m. for triplicates. Genotypes of cells are as
indicated. (c) Shown are western blot analyses of protein lysates from HCT116 cells transfected for 48h with cDNA as indicated.
(d) Immunohistochemistry using an antibody against Sox9 for parafﬁn-embedded polyps from small intestine (SI) and large intestine
(LI). Genotypes of mice are as indicated. Scale bar¼50mm.
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Mice
Mice were housed in a pathogen-free environment and
observed daily for signs of ill health. Hic1
þ/  females were
crossed to Apc
þ/D716 males to generate mice used in the studies
described. Both strains were backcrossed as described pre-
viously (Oshima et al., 1995; Chen et al., 2003; Briggs et al.,
2008) and maintained in a C57BL/6 background. Genotyping
was performed as described previously (Oshima et al., 1995;
Carter et al., 2000).
Polyp counts
Mice were killed at 60 or 90 days by CO2 asphyxiation. The
intestinal tract was removed, opened longitudinally and
washed with PBS, as described previously (Moser et al.,
1990). The cleared tissue was ﬁxed in 10% buffered formalin
and subsequently stained with 1.5% methylene blue in
physiological saline (0.9%). Intestines were destained with
10% ethanol using several changes of fresh destaining solution
to attain the desired level of stain. At this level, intestinal tissue
appeared light blue with signiﬁcantly darker polyps. The
proximal, medial and distal regions of the small intestine and
the entire large intestine were examined. Polyps were scored
with a dissecting microscope by at least two independent
observers, and the average counts were further analyzed.
Student’s t-test was used to compare the mean allele count
between DH and Apc for 60 days by anatomical regions and
subregions. All comparisons were considered statistically
signiﬁcant at a P-value o0.05 (*) or P-value o0.1 (**). All
statistical analyses were performed using Stata 10 statistical
package.
Immunohistochemistry
Hic1 immunohistochemistry was performed as previously
described (Chen et al., 2003). Antigen retrieval for deparafﬁ-
nized tissue sections was performed in citrate buffer (small
intestine) or Tris-EDTA buffer (colon) for 20min by using a
steamer. Following blocking of endogenous peroxidase,
parafﬁn-embedded sections were submitted to immunohisto-
chemistry using the Vectastain Elite ABC system (Vector
Laboratories, Burlingame, CA, USA). Citrate buffer antigen
retrieval and Vectastain ABC kits (Vector Laboratories) were
used for all other immunohistochemistry. The following
antibodies were used: Sox9 (Chemicon, Billerica, MA, USA),
b-Catenin (BD Transduction Laboratories, Sparks, MD,
USA), Ki67 (Novocastra Laboratories, Newcastle upon Tyne,
UK) and Sirt1 (Upstate Biotechnology, Billerica, MA, USA).
Crypt counting
Ki67 staining was used to mark crypt cells within sections
prepared, as described above. Images were collected at  20
magniﬁcation throughout the small intestine, and at least 21
ﬁelds from 4 mice across all genotypes were utilized. Crypt
hyperplasia was documented by counting crypts as described
previously with some modiﬁcation (Stuber et al., 1998; Boivin
et al., 2003). In the current study, the number of crypts and
intestinal villi were counted for each image by two independent
observers, and the average of the two counts was used in the
data analysis.
Bisulﬁte sequencing
Genomic DNA extraction and bisulﬁte modiﬁcation, and
sequencing of tissue derived from WT, Hic1
þ/ , Apc
þ/D716 and
DH mice was performed as previously described (Frommer
et al., 1992; Chen et al., 2003). Primers used were within Hic1a
and 1b promoters as previously described (Chen et al., 2003).
Sequences are available upon request. An average of 68 alleles
was sequenced for each genotype for Hic1a, whereas an
average of 20 alleles for each was analyzed for Hic1b.
Weighted means were generated and statistical analyses
performed are as follows: the generalized estimating equation
data analysis, assuming independent correlation structure with
robust standard error estimates and Gaussian distribution was
used to calculate the mean percent methylation per allele, and
corresponding standard errors for each genotype. To control
for multiple testing, Sidak adjustment method was used to
correct for family-wise error rate. All statistical analyses were
performed using Stata version 10 statistical package and are
shown in Supplementary Table 2.
Preparation of MEFs
MEFs from E10.5 mouse embryos were prepared as described
previously (Briggs et al., 2008). Early passage (p2) MEFs were
seeded at a density of 2 10
5 per well in a six-well plate. The
cells were maintained in DMEM (Cellgro, Manassas, VA,
USA) supplemented with 10% bovine calf serum (HyClone,
Hudson, NH, USA) and antibiotics, and grown at 371Ci n
5% CO2 atmosphere.
RNA preparation and real-time analysis
Total RNA was isolated from cell pellets and DNase 1 treated
using RNeasy (Qiagen, Valencia, CA, USA). Real-time PCR
was performed using conditions and primers described
previously, including initial normalization to GAPDH.
Cell culture
Cell lines were maintained according to ATCC guidelines.
All transfections were performed using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA), according to manufacturer’s
instructions.
Western analysis
Antibodies used were: Sox9 (Chemicon) and V5 (Invitrogen).
b-Actin (Sigma, St Louis, MO, USA) was used as a loading
control.
ChIP
ChIP was carried out on HCT116 cells transfected as
described above. ChIP was performed as described previously
(McGarvey et al., 2006) using V5 antibody (Invitrogen) or IgG
control (Millipore, Billerica, MA, USA).
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